1.74
1.74 (0%)
As of Apr 17, 2025
Bioxcel Therapeutics, Inc. [BTAI]
Source:
Company Overview
BioXcel Therapeutics, Inc is a biopharmaceutical company utilizing artificial intelligence (“AI”) to develop transformative medicines in neuroscience and, through the Company’s wholly owned subsidiary, OnkosXcel Therapeutics LLC (“OnkosXcel”), immuno-oncology.
| Country | United States |
| Headquarters | new haven, connecticut |
| Phone Number | 203-643-8060 |
| Industry | manufacturing |
| CEO | Vimal Mehta Mehta, Ph.D. |
| Website | www.bioxceltherapeutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $2.3 |
| Operating Profit | $-67.2 |
| Net Income | $-59.6 |
| Net Cash | $-35.4 |
Profit Ratios
| Gross Margin | $0.1 |
| Operating Margin | -2,967.6 |
| Profit as % of Revenues | -0.2% |
| Profit as % of Assets | -106.4% |
| Profit as % of Stockholder Equity | 64% |
Management Effectiveness
| Return on Equity | 64% |
| Return on Assets | -155.5% |
| Turnover Ratio | 4% |
| EBITA | $-67.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $38.3 |
| Total Liabilities | $131.4 |
| Operating Cash Flow | $-72 |
| Investing Cash Flow | $0 |
| Financing Cash Flow | $36.7 |
